Beam Therapeutics Inc. (BEAM) Stock Overview
Explore Beam Therapeutics Inc.’s financial performance, market position, analyst ratings, and future outlook.
Beam Therapeutics Inc. (BEAM)
Key Financials
Key Financials
Market Cap
3.5B
P/E Ratio
-54.20
EPS (TTM)
$-0.49
ROE
-0.06%
BEAM Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of Beam Therapeutics Inc. (BEAM) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of C+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
The current technical analysis reveals key indicators including an RSI of 62.04, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $30.75.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -54.20 and a market capitalization of 3.5B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.